Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy
>24 h). While additional optimization will be required to further improve its drug-like profile, TC7 emerged as the most promising compound evaluated in this study and represents a suitable starting point for future development. Collectively, these results serve as a proof of concept supporting a potential new codrugs strategy combining HO-1 and cSRC inhibition for glioblastoma therapy.
Authors
- Marica Erminia Schiano (ORCID: https://orcid.org/0000-0002-4456-3003)
- Valeria Sorrenti (ORCID: https://orcid.org/0000-0002-5973-1495)
- Agata Grazia D’Amico (ORCID: https://orcid.org/0000-0003-4216-417X)
- Modica Maria (ORCID: https://orcid.org/0000-0002-6350-931X)
- Sebastiano Intagliata (ORCID: https://orcid.org/0000-0002-0201-1745)
- Luca Vanella (ORCID: https://orcid.org/0000-0002-6314-6029)
- Federica Sodano (ORCID: https://orcid.org/0000-0003-2013-4893)
- Valeria Consoli (ORCID: https://orcid.org/0000-0001-8961-5818)
- Valeria Pittalà (ORCID: https://orcid.org/0000-0003-1856-0308)
- Giuseppe Romeo (ORCID: https://orcid.org/0000-0003-2160-4164)
- Loredana Salerno (ORCID: https://orcid.org/0000-0001-6458-3717)
- Sara Mocka (ORCID: https://orcid.org/0009-0005-5060-0965)
- Chiara Terlati
- Mohamed Helal (ORCID: https://orcid.org/0000-0002-6304-8285)
- Giorgia Centamore
Institutions
- Suez Canal University (EG)
- University of Catania (IT)
- Zewail City of Science and Technology (EG)
- University of Naples Federico II (IT)
Publication Details
- Journal
- RSC Medicinal Chemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1039/d6md00227g
- Primary Topic
- Heterocyclic Compound Synthesis and Bioactivity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Ministero della Salute
- Università di Catania
- Ministero dell'Università e della Ricerca